{
    "nct_id": "NCT04562389",
    "official_title": "A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-naïve Patients with Myelofibrosis",
    "inclusion_criteria": "* Aged ≥ 18 years\n* A diagnosis of primary MF or post-essential thrombocythemia (ET) or postpolycythemia- vera (PV) MF.\n* Active symptoms of MF as determined by presence of at least 2 symptoms using the Myelofibrosis Symptom Assessment Form (MFSAF) V4.0.\n* Participants with international prognostic scoring system (DIPSS) risk category of intermediate-1, or intermediate-2, or high-risk.\n* Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than or equal to (>=) 450 cubic centimeter (cm^3) .\n* Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (<=) 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase).\n* Previous treatment with JAK inhibitors for MF.\n* Previous treatment with selinexor or other XPO1 inhibitors.",
    "miscellaneous_criteria": ""
}